Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Cancer biology company collaborates with ACLARA on cancer biomarkers
December 28th, 2004
Iceland Genomics Corporation (IGC) has entered into an agreement with ACLARA BioSciences (ACLA) under which ACLARA will use its proprietary eTag assaid to analyze tumor samples from cancer patients provided by IGC to validate candidate biomarkers and their utility as indicators of disease progression and as predictors of a likely response of individual patients to particular therapies. Under the agreement, Iceland Genomics will provide to ACLARA tumor and blood samples and blinded patient data, including treatment histories and outcomes. ACLARA will test the samples with its eTag assaid to help validate the parameters measured as biomarkers. ACLARA...
Source: Cancer Weekly (2004-12-28)
|
